BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/22/2022 4:46:09 AM | Browse: 573 | Download: 1402
Publication Name World Journal of Virology
Manuscript ID 70181
Country Greece
ISSN 2220-3249 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Virology
Manuscript Type Opinion Review
Article Title Rifampicin for COVID-19
Manuscript Source Unsolicited Manuscript
All Author List George D Panayiotakopoulos and Dimitrios T Papadimitriou
ORCID
Author(s) ORCID Number
George D Panayiotakopoulos http://orcid.org/0000-0002-9303-8854
Dimitrios T Papadimitriou http://orcid.org/0000-0002-6083-3560
Funding Agency and Grant Number
Corresponding Author Dimitrios T Papadimitriou, MD, MSc, PhD, Academic Fellow, Director, Director, Department of Pediatric, Adolescent Endocrinology & Diabetes, Athens Medical Center, 58 av. Kifisias , Marousi 15125, Greece. info@pedoendo.net
Key Words COVID-19; SARS-CoV-2; Rifampicin; Antiviral activity; RNA polymerase
Core Tip Rifampicin may prove pharmacologically effective, supplying a possible and cost-effective solution to the global battle against severe acute respiratory syndrome coronavirus 2, not only for treatment but also for chemoprophylaxis of those at higher risk. It is also possible to administer rifampicin by nebulization. The publications describing the in vitro mechanisms and providing proof of clinical efficacy of rifampicin against RNA viruses with their own RNA polymerase have emerged since 1969-1971. Recent in silico studies using a computer-aided approach, found rifampicin among the most promising existing drugs that can be repurposed for the treatment of coronavirus disease-2019.
Publish Date 2022-03-22 04:46
Citation Panayiotakopoulos GD, Papadimitriou DT. Rifampicin for COVID-19. World J Virol 2022; 11(2): 90-97
URL https://www.wjgnet.com/2220-3249/full/v11/i2/90.htm
DOI https://dx.doi.org/10.5501/wjv.v11.i2.90
Full Article (PDF) WJV-11-90.pdf
Full Article (Word) WJV-11-90.docx